The Next
Generation
Triple Agonist
Retatrutide simultaneously activates three metabolic receptors — GIP, GLP-1, and glucagon. Independent, evidence-based research on what that means for metabolic health in Aotearoa.
TRIUMPH-4: 28.7% Mean Weight Loss at 68 Weeks
Breaking down Lilly’s first successful Phase 3 readout in obesity with knee osteoarthritis — the numbers, the caveats, and what it means.
Triple Receptor Agonism: Why the GCGR Target Changes Everything
How glucagon receptor activation sets retatrutide apart from existing GLP-1 therapies.
Research-Use Peptides in New Zealand: A Legal & Practical Overview
Regulatory landscape, compounding context, and what researchers need to know.
Three Targets.
One Molecule.
Where semaglutide and tirzepatide act on one or two receptors, retatrutide (LY3437943) is a once-weekly injectable peptide that simultaneously activates the GIP, GLP-1, and glucagon receptors — the first of its kind to reach late-stage clinical development.
The additional glucagon receptor component drives significantly greater energy expenditure and fat oxidation compared to GLP-1 monotherapy, which researchers believe explains the substantially higher weight loss figures seen in trials.
-
GLPreceptorGLP-1 Receptor AgonismReduces appetite and food intake. Slows gastric emptying. Shared mechanism with semaglutide and tirzepatide.
-
GIPreceptorGIP Receptor AgonismEnhances insulin secretion and potentially improves GLP-1 receptor sensitivity. Also active in tirzepatide.
-
GCGreceptorGlucagon Receptor AgonismThe third target — increases energy expenditure, drives hepatic fat reduction, and appears responsible for retatrutide’s superior weight loss profile.
Latest Research
& Analysis
All Articles
TRIUMPH-4 Dissected: What 28.7% Weight Loss at 68 Weeks Actually Means
A methodical breakdown of Lilly’s December 2025 Phase 3 topline release — efficacy estimands, knee osteoarthritis context, dose arms, and what the headline number does and does not tell us.
Retatrutide vs Tirzepatide: The Triple vs Dual Agonist Question
Does the glucagon receptor target justify the trade-offs? A clinical comparison.
Retatrutide in NZ: Regulatory Status, Research Access & Practical Guide
What New Zealanders doing metabolic research need to understand about access and the current regulatory framework.
The numbers
behind the latest TRIUMPH headline
This page now includes Lilly’s December 2025 TRIUMPH-4 topline Phase 3 results alongside earlier published Phase 2 research. TRIUMPH-4 has not yet been fully peer reviewed. This site presents research information only. Individual outcomes vary. Not medical advice.
Stay current with
the trial data
Phase 3 results, new publications, and NZ-specific updates — sent when there’s something worth reading. No noise.
Research updates only · Unsubscribe anytime